2020
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma
Kaley TJ, Panageas KS, Pentsova EI, Mellinghoff IK, Nolan C, Gavrilovic I, DeAngelis LM, Abrey LE, Holland EC, Omuro A, Lacouture ME, Ludwig E, Lassman AB. Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. Annals Of Clinical And Translational Neurology 2020, 7: 429-436. PMID: 32293798, PMCID: PMC7187704, DOI: 10.1002/acn3.51009.Peer-Reviewed Original ResearchConceptsRecurrent malignant gliomaDose-limiting toxicityMTOR inhibitor temsirolimusMalignant gliomasAkt inhibitor perifosinePhase I clinical trialDose level 3Dose level 7Phase II doseSynergistic anti-tumor effectKarnofsky performance statusPhase I trialDeadly primary brain cancerPI3K/Akt/mTOR axisPrimary brain cancerAkt/mTOR axisAnti-tumor effectsPotential therapeutic targetMost malignant gliomasPrior therapyTemsirolimus dosePerformance statusI trialIntracerebral hemorrhageCombined therapy
2014
TM-01IDENTIFICATION OF GLUCOSE-6-PHOSPHATASE ALPHA AS A KEY METABOLIC REGULATOR FOR GLIOBLASTOMA CELL INVASION
Abbadi S, Rodarte J, Abutaleb A, Lavell E, Smith C, Ruff W, Schiller J, Olivi A, Levchenko A, Guerrero-Cazares H, Quinones-Hinojosa A. TM-01IDENTIFICATION OF GLUCOSE-6-PHOSPHATASE ALPHA AS A KEY METABOLIC REGULATOR FOR GLIOBLASTOMA CELL INVASION. Neuro-Oncology 2014, 16: v213-v213. PMCID: PMC4218619, DOI: 10.1093/neuonc/nou278.1.Peer-Reviewed Original ResearchBrain tumor initiating cellsGlycolytic inhibitionGlioblastoma cell invasionSuch reprogrammingKnockdown cellsMetabolic reprogrammingTumor initiating cellsKey enzymeGlycogen synthaseCell survivalAggressive primary brain cancerCell invasionComplete rescueFunctional consequencesPotential therapeutic targetPrimary brain cancerGBM cellsWild-type miceG6PCReprogrammingInitiating cellsGlycogen accumulationGlycogen phosphorylaseMalignant progressionKnockdown
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply